Humalog Mix 25 100 Iu/ml 3 ML Cartridge

• Type 1 and Type 2 diabetes mellitus

Like any other medicine, Humalog Mix 25 100 Iu/ml 3 ML also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Weight gain
• Infusion site reaction
• Hypoglycemia (low blood glucose level)
• Edema (swelling)
• Skin rash
• Lipodystrophy (skin thickening or pits at the injection site)

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Humalog Mix 25 100 Iu/ml 3 ML Cartridge is available in injection form and is advised to be taken as per the doctor's prescription. It should be administered by a doctor or experienced nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  

• Humalog Mix 25 100 Iu/ml 3 ML Cartridge is a combination of two drugs such as Insulin Lispro (25%) and Insulin Lispro Protamine (75%) as an active ingredient.
• It is a fast-acting insulin in which Insulin Lispro has a fast onset of action and on the other hand lispro protamine has a prolonged duration of action.
• Together both the composition of this medicine ensure rapid as well as consistent sugar control by facilitating the reuptake of sugar in muscle and fat cells and also suppressing the production of sugar in the liver.
  

• Arakaki, R. F., Blevins, T. C., Wise, J. K., Liljenquist, D. R., Jiang, H. H., Jacobson, J. G., ... & Jackson, J. A. (2014). Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open‐label trial. Diabetes, Obesity and Metabolism, 16(6), 510-518. https://pubmed.ncbi.nlm.nih.gov/24298995/
• Roach, P., & Woodworth, J. R. (2002). Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clinical pharmacokinetics, 41(13), 1043-1057. https://pubmed.ncbi.nlm.nih.gov/12403642/
• Ceriello, A., Cremasco, F., Romoli, E., Rossi, A., & Gentilella, R. (2012). Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data. Expert Opinion on Pharmacotherapy, 13(2), 255-281. https://pubmed.ncbi.nlm.nih.gov/22242803/
• Bowering, K., Reed, V. A., Felicio, J., Landry, J., Ji, L., & Oliveira, J. (2012). A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with type 2 diabetes who have inadequate glycaemic control on oral anti‐hyperglycaemic medication: results of the PARADIGM study. Diabetic Medicine, 29(9), e263-e272. https://pubmed.ncbi.nlm.nih.gov/22672081/
• Roach, P., Trautmann, M., Arora, V., Sun, B., Anderson Jr, J. H., & Mix50 Study Group. (1999). Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clinical therapeutics, 21(3), 523-534. https://pubmed.ncbi.nlm.nih.gov/10321421/